A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 454
- Population
- ALL · 60 Years
- Duration
- 2012-12-01 to 2015-04-01
- Intervention
- LCZ696; Olmesartan; LCZ696 matching placebo; Olmesartan matching placebo; amlodipine; hydrochlorothiazide
- Comparator
- Olmesartan
- Outcomes measured
- Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks — baseline, 12 weeks; Change From Baseline in Mean Central Pulse (CPP) Pressure — Baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean Pulse Wave Velocity (PWV) — baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks — baseline, 52 weeks; Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean Sitting Pulse Pressure (msPP) — baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean Arterial Pressure (MAP) — baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP) — Baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP) — Baseline, 12 weeks, and 52 weeks; Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP) — Baseline, 12 weeks, and 52 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cardiovascular ageing · 100%Title contains controlled term: arterial stiffness. Abstract contains controlled term: arterial stiffness. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.